At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 191 enrolled
Drug / intervention
MK1903 +1 moredrug
Likely dose
MK1903 150 mg (three 50 mg capsules) by mouth every 8 hours for 4 weeksAI-extracted
Key inclusion· 3
- ✓Not currently on a statin or other lipid-modifying therapy
- ✓Low or moderate cardiovascular risk
- ✓Male participants or females of non-reproductive potential
Key exclusion· 16
- ✕Female of reproductive potential
- ✕Pregnant, breastfeeding, or planning to conceive during study
- ✕Cancer history within 5 years (except certain skin and cervical cancers)
- ✕Recent or ongoing drug or alcohol abuse
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Lipid-Modifying Effect and Tolerability of MK1903 in Patients With Dyslipidemia
In Brief
A Phase 2 clinical trial evaluating MK1903 and Comparator: Placebo for Dyslipidemia. Completed, enrolled 191 participants.
Detailed Summary
This study will evaluate the lipid-modifying effect and tolerability of MK1903 when compared to placebo in patients with dyslipidemia who are not on a statin or other lipid-modifying therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidemia
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2008
First PostedFeb 2009
Primary CompletionSep 2009
TodayJul 2026
First PostedFeb 19, 2009
Enrollment StartJun 1, 2008
Primary CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.4 years ago
Interventions
MK1903drug
Three 50 mg capsules MK1903 by mouth every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period.
Comparator: Placebodrug
Three 50 mg capsules placebo to MK1903 every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period.